<code id='C5888966DC'></code><style id='C5888966DC'></style>
    • <acronym id='C5888966DC'></acronym>
      <center id='C5888966DC'><center id='C5888966DC'><tfoot id='C5888966DC'></tfoot></center><abbr id='C5888966DC'><dir id='C5888966DC'><tfoot id='C5888966DC'></tfoot><noframes id='C5888966DC'>

    • <optgroup id='C5888966DC'><strike id='C5888966DC'><sup id='C5888966DC'></sup></strike><code id='C5888966DC'></code></optgroup>
        1. <b id='C5888966DC'><label id='C5888966DC'><select id='C5888966DC'><dt id='C5888966DC'><span id='C5888966DC'></span></dt></select></label></b><u id='C5888966DC'></u>
          <i id='C5888966DC'><strike id='C5888966DC'><tt id='C5888966DC'><pre id='C5888966DC'></pre></tt></strike></i>

          focus

          focus

          author:entertainment    Page View:94
          In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
          Scott Olson/Getty Images

          WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

          The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 

          advertisement

          The negotiated prices won’t take effect until 2026. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more
          Surge in Apellis stock fueled by confidence in safety of its eye drug
          Surge in Apellis stock fueled by confidence in safety of its eye drug

          MollyFerguson/STATSharesofApellisPharmaceuticalsarerebounding,drivenbyagrowingbeliefamongsomeinvesto

          read more
          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more

          A fraught question for the kids of Alzheimer’s: Is it coming for us?

          Mysisterhasafantasyaboutouroldage:Sheimaginesthatthesevensiblingsinourfamilywillbelivingtogetheragai